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Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of
renal cell carcinomas. This characteristic has supported the rationale of targeting VEGF-driven tumour
vascularization, especially in clear cell RCC. VEGF-inhibiting strategies include the use of tyrosine kinase
inhibitors (sunitinib, axitinib, pazopanib, and sorafenib) and neutralizing antibodies such as bev-
acizumab.
Hypertension (HTN) is one of the most common adverse effects of angiogenesis inhibitors. HTN ob-
served in clinical trials appears to correlate with the potency of VEGF kinase inhibitor against VEGFR-2:
agents with higher potency are associated with a higher incidence of HTN. Although the exact mechanism
by tyrosine kinase inhibitors induce HTN has not yet been completely clariﬁed, two key hypotheses have
been postulated. First, some studies have pointed to a VEGF inhibitors-induced decrease in nitric oxide
synthase (NOS) and nitric oxide (NO) production, that can result in vasoconstriction and increased blood
pressure. VEGF, mediated by PI3K/Akt and MAPK pathway, upregulates the endothelial nitric oxide syn-
thase enzyme leading to up-regulation of NO production. So inhibition of signaling through the VEGF
pathway would lead to a decrease in NO production, resulting in an increase in vascular resistance and
blood pressure. Secondly a decrease in the number of microvascular endothelial cells and subsequent
depletion of normal microvessel density (rarefaction) occurs upon VEGF signaling inhibition.
NO donors could be successfully used not only for the treatment of developed angiogenesis-inhibitor-
induced hypertension but also for preventive effects.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Every year more than 270,000 new cases of kidney cancer are
diagnosed worldwide in Europe 40% of patients with renal cancer
die from this disease. Surgery is the treatment of choice in patients
with tumors limited to the kidney, whereas in metastatic disease
systemic therapy is often used.
The Von Hippel Lindau (VHL) protein plays a central role in the
pathogenesis of clear cell renal carcinoma [1]. In a normoxic state,
pVHL allows degradation of HIF. HIF-alpha is responsible for in-
ducing expression of genes associated with angiogenesis andB.V. This is an open access article u
ynthase; VEGF, Vascular en-
growth factor receptor; RCC,
e and Cancer, edited by Jordi
ón-Mateos),proliferation, such as vascular endothelial growth factor receptor
(VEGF), platelet-derived growth factor receptors (PDGF), and TGF-
alpha. While HIF is mostly active in hypoxic conditions, VHL de-
fective renal carcinoma shows constitutive activation of HIF even
in oxygenated environments. Intracellular accumulation of HIF-
alpha stimulates the transcription of genes regulating VEGF, PDGF
and TGF-alpha.
For many years inmunotherapy with high dose IL-2 was the
only treatment used in this disease. However efﬁcacy of this agent
is low, with important toxicity associated although complete re-
sponses could be obtained in some patients. In the last years tyr-
osine kinase inhibitors (TKI), mTOR inhibitors, new in-
munotherapy agents and other drugs have changed the choices
available for use.
Anti VEGF and antiVEGFR agents are effective mainly in clear
cell renal carcinoma because VEGF is elevated in the majority of
these tumors. Hypertension (HTN) is commonly associated with
angiogenesis inhibitors that target the VEGF pathway and appears
to be a generalized effect of this class of agents, including suniti-
nib, axitinib, pazopanib, sorafenib and bevacizumab, which arender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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expression
Fig. 1. Hypertension induced by VEGF inhibitors. VEGF: vascular endothelial
growth factor; NO: nitric oxide. HTN: hypertension.
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cinoma [2,3]. The reported incidence of all-grade HTN ranges from
25% with sorafenib and sunitinib, to 40% with axitinib and pazo-
panib. In addition, multiple case reports have described acute
hypertensive complications of therapy with anti-VEGF therapies
such as malignant HTN and posterior reversible encephalopathy
syndrome [4,5].
Physiologically, HTN develops when inhibition of VEGF causes a
decrease in production of nitric oxide and prostacyclin in vascular
endothelial cells (Fig. 1) [6]. There is evidence to suggest that HTN
may result from structural or functional vascular rarefaction
caused by inhibition of angiogenic growth factors [7].
Side adverse events (SAEs) were graded according to the Na-
tional Cancer Institute Common Terminology Criteria for Adverse
Events (CTCAE), version 3.0. HTN was deﬁned by either maximum
or mean systolic blood pressure (SBP) of at least 140 mmHg or
diastolic blood pressure (DBP) of at least 90 mmHg, as measured in
the clinic on days 1 and 28 of each 6-week treatment cycle at any
time during the study after the ﬁrst dose of sunitinib.2. Sunitinib mechanism of action
Sunitinib malate (Sutent; Pﬁzer, New York, USA) is a multi-
targeted tyrosine kinase inhibitor used in the treatment of meta-
static renal cell carcinomas (RCC) and gastrointestinal stromal
tumours, and is under evaluation for other malignancies [8]. Su-
nitinib malate inhibits the VEGFR type 1 and type 2 (FLT1 and
FLT1/ KDR), platelet-derived growth factor receptors, stem cell
factor receptor (c-KIT) and FLT3 and RET kinases
In a randomized phase III trial in ﬁrst-line therapy for metas-
tastic renal cell carcinoma [9,10], sunitinib was superior to inter-
feron-α in progression-free-survival (PFS; 11 vs 5 months;
po0.001) and objective response rate (ORR; 47% vs 12%;
po0.001); in addition, median overall survival (OS) with sunitinib
was 26.4 vs 21.9 months with interferon-α. Based on these data,
sunitinib is currently one of the choices in the treatment for pa-
tients with advanced renal cell carcinoma.
Toxicity of sunitib was acceptable; all-grade and grade 3–4 HTN
occurred in 30% and 12% of patients treated with this drug, re-
spectively [10]. In the sunitinib expanded-access study, the in-
cidence of all-grade HTN was 22% and grades 3–4 was 5% [11].
Inhibition of the VEGF receptor might increase vascular resistance,
caused by decreased nitric oxide and prostacyclin production, as
well as provoke vascular rarefaction and increased arterial stiff-
ness, resulting in HTN [12].Sunitinib treatment-induced HTN was associated with statis-
tically signiﬁcantly improved clinical outcome. These ﬁndings
support the hypothesis that HTN may be a viable biomarker of
antitumor efﬁcacy in this patient population, although develop-
ment of HTN during sunitinib treatment was neither necessary nor
sufﬁcient for clinical beneﬁt in all patients.3. Sunitinib induced hypertension
Although several reports have been published on the patho-
genesis of HTN secondary to VEGF signaling inhibitors, it exact
molecular mechanisms behind has not yet been clearly elucidated.
Nitric oxide pathway inhibition decrease in the density of micro-
vessels (rarefaction), increase in oxidative stress, imbalance be-
tween endothelin-1 (ET-1) and VEGF, glomerular injury develop-
ing from loss of VEGF effect, and changes in neurohormonal fac-
tors or the renin-angiotensin-aldosterone represent some of the
main proposed mechanisms [13,14].
Previous studies have shown that VEGFR-2 is involved in the
regulation of vascular tone. Activation of VEGFR-2 via phosphoi-
nositide 3-kinase (PI3K) and its downstream serine protein kinase
(Akt) stimulates endothelium-derived nitric oxide syntase, leading
to the production of the potent vasodilator NO. In addition, de-
creased NO bioavailability disturbs the balance between the va-
sodilator NO and ET-1, favoring ET-1 production and thereby in-
ducing further vasoconstriction and an additional rise in blood
pressure [15,16]. Indeed, plasma ET-1 concentrations have been
shown to increase in sunitinib treated patients [17].
Predisposing factors for the development of HTN during
treatment with TKIs included gene polymorphims associated with
the regulation of blood pressure. In a study in patients with me-
tastatic renal cell carcinoma and GIST, several single-nucleotide
polymorphisms (SNPs) in speciﬁc genes encoding for metabolizing
enzymes, efﬂux transporters, and drug targets were associated
with sunitinib-induced toxicities [18]. Polymorphisms in VEGFA,
VEGFR-2 and in the downstream mediators eNOS and ET-1 may be
important factors in blood pressure changes [7]. The analysis on
polymorphisms genes showed that, during sunitinib therapy, an
ACG haplotype in VEGFA is signiﬁcantly associated with greater
elevations in the levels of systolic blood pressure and also with the
incidence of grade 3 HTN. In addition, the presence of and eNOS
-786 allele was related to a increase in the risk of grade 3 HTN [19].
3.1. Oxidative stress
The shear stress-induced activation of eNOS seems to be de-
pendent on the activation of the PI3K/Akt pathway [20]. Akt has
been reported to be activated by Caþ þ-dependent stimulation of
calmodulin-dependent protein kinase. However, the shear-stress-
induced phosphorylation of Akt was completely unaffected by the
removal of extracellular Caþ þ . Taken together, research published
results show that the stimulation of PI3K/Akt by shear stress and
VEGF elicits the serine phosphorylation of eNOS, and thereby en-
hances enzyme activity in a Caþ þ-independent manner [20].
VEGF-dependent and VEGF-independent (shear stress) activa-
tion of VEGFR-2 gives rise to the increased production of NO and
prostacyclin in vascular endothelial cells [21]. Inhibition of these
vasodilatory mechanisms subsequently results in increased per-
ipheral vascular resistance and HTN. Increased endothelial shear
stress can activate eNOS activity directly, presumably through a
VEGF-independent mechanism [20]. Although shear-stress-medi-
ated phosphorylation of eNOS is thought to regulate enzyme ac-
tivity, the mechanism of activation of eNOS is not yet known.
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Another possible mechanism causing HTN relates to a decrease
in the number of small arteries and arterioles (rarefaction) in re-
sponse to VEGF kinase inhibitors. New clinical data support the
appearance of rarefaction in patients treated with VEGF inhibitors
[7]. Studies in hypertensive rat models shows that rarefaction is an
early event during HTN. Noon et al. suggested that capillary rar-
efaction in young adults with a familial predisposition to HTN (as a
result of defective angiogenesis) was a cause rather than a con-
sequence of HTN [22]. Microvascular rarefaction has been con-
sistently demonstrated in adults with HTN.
Despite the fact that is unclear whether the rarefaction is
structural (disappearance of capillaries), functional (non-perfusion
of capillaries), or a contribution of both, it is likely that this phe-
nomenon contributes to the HTN observed in patients treated with
VEGF kinase inhibitors.
3.3. Imbalance between ET-1 and VEGF
Endothelial dysfunction reduces nitric oxide production and
leads to vasoconstriction. Enhanced secretion of ET-1, a potent
vasoconstrictor peptide from endothelial cells [7] result in in-
creased peripheral resistance. However, ET-1 is more likely to in-
ﬂuence the local vascular bed than systemic vascular bed.
Some authors have demonstrated a stimulatory interaction
between VEGF and ET-1 on each other's gene expression in arterial
endothelial cells and vascular smooth muscle cells, suggesting an
interplay between these two important pathways that regulate
vascular tone [23]. Therefore, it is possible that VEGF kinase in-
hibitors drugs could cause an imbalance between ET-1 and VEGF,
thus contributing to HTN.
3.4. Glomerular injury
VEGF inhibition may also contribute to HTN by other me-
chanisms: the proximal tubule natriuretic response to elevated
blood pressure is partially dependent on cGMP, and VEGF-targeted
therapies might suppress this response, perpetuating the rise of
blood pressure. In patients on VEGF inhibitors, albumin/creatinine
ratio was elevated, and there was a higher incidence of macro-
albuminuria than in patients not on VEGF inhibitors [24].
Inhibition of podocyte-endothelial cell VEGF signaling causes
endotheliosis, thrombotic microangiopathy, and narrowing of the
capillary lumen, the pathological lesion seen in human kidney
biopsy specimens from patients with albuminuria receiving VEGF-
targeted therapies [24].
3.5. The nitric oxide signaling pathway
NO was originally recognized as a free radical signaling mole-
cule that was naturally produced in the human body. The en-
dogenous source of NO in the body was early discovered to be
secondary to metabolism of L-arginine by a family of enzymes
known as NO synthases (NOSs). These enzymes utilize the sub-
strates L-arginine, molecular oxygen, and NADPH to produce L-ci-
trulline and NO (Fig. 1). Two of the NOS isoforms are expressed
constitutively (endothelial NOS, NOS-III, or eNOS and neuronal
NOS, NOS-I, or nNOS), whereas one isoform is inducible in mul-
tiple cell types and tissues (inducible NOS, NOS-II, or iNOS) eNOS,
as it own name implies, is produced by the vascular endothelium
and is the most important isoform in regulating NO production to
inﬂuence the vascular system.
NO is a highly reactive, diffusible molecule, with a short half-
life. This makes it an ideal signaling molecule to act in an autocrine
or paracrine fashion. NO regulates vasodilation via effects onsoluble guanylate cyclase to produce cyclic guanosine monopho-
sphate (cGMP) [25–27]. Other important vasoregulatory properties
of NO include regulation of smooth muscle cell proliferation and
migration, platelet aggregation, and leucocyte adhesion to the
endothelium.
Also it has been discovered that NO could be produced en-
dogenously in the body via an L-arginine and NOS-independent
mechanism from the anion nitrite (NO2) [28]. Nitrite was
thought to be a relatively stable end-product of NO metabolism
that had no signiﬁcant biological action. Bryan et al. showed that
affects cyclic GMP production, cytochrome P450 activities, and
heat shock protein 70 and heme oxygenase-1 expression in a
variety of tissues [29].
The arginine/NOS/NO pathway appears be very important in
regulating vascular tone and remodeling in blood pressure(BP).
Changes in NOS expression and increased NO generation are
generally interpreted to be a protective compensatory response to
the underlying disease processes that increase vascular resistance.
The vasodilatory properties of NO are well characterized and are
clearly important in the setting of BP. NO can decrease smooth
muscle cell proliferation, but may also protect via increased
apoptosis or autophagic signaling to limit the progression of vas-
cular lesions and to remodel the vascular wall [30].
Nitric oxide produced by the endothelial NO synthase is a
fundamental determinant of cardiovascular homeostasis: it reg-
ulates systemic BP, vascular remodeling and angiogenesis [26].
Physiologically, the most important stimulus for the continuous
formation of NO is the viscous drag (shear stress) generated by the
streaming blood on the endothelial layer.
3.6. Vascular endothelial growth factor
Vascular endothelial growth factor plays a fundamental role in
physiological and pathologic angiogenesis. As a potent mitogen
speciﬁcally for endothelial cells, VEGF has been shown to promote
endothelial cell proliferation and migration in vitro and to induce a
strong angiogenic response in peripheral vascular ischemia
[13,31].
Although the characteristics of VEGF in pathologic angiogenesis
have been extensively studied, the mechanism responsible for
VEGF-induced vasodilation is not completely clear. VEGF initiates
vasodilation or vasorelaxation in vitro and in vivo [13]. In animals,
VEGF induces endothelium-dependent vasorelaxation or vasodi-
lation, in which nitric oxide, but not PGI2, is found to be the main
regulator. VEGF exerts multiple biologic effects through its inter-
action with two receptor tyrosine kinases, Flt-1 (VEGF receptor 1)
and KDR (VEGF receptor 2). Flt-1 is required for endothelial mor-
phogenesis, and KDR is involved primarily in mitogenesis [32].
VEGF stimulates production of vasodilatory nitric oxide via ac-
tivation of endothelial NO synthase and also upregulates vasodila-
tory prostacyclin. Small molecule VEGF-targeted therapies inhibit
the nitrate pathway in vitro, and in humans, HTN often develops
within the ﬁrst few days of treatment, consistent with acute sup-
pression of NO-and/or prostacyclin-mediated vasodilation [33].
Vascular endothelial growth factor exerts vasodilation-induced
hypotension, which is likely mediated by oxide nitric and pros-
taglandin I2. The hypotension induced by acute administration of
VEGF is transient and dose-rate dependent and usually can be
tolerated in normal animals. VEGFR-2 is the predominant receptor
that mediates production of nitric oxide and prostacyclin by en-
dothelial cells, leading to vasodilation. In contrast, inhibition of
VEGFR signaling increases blood pressure [2].
Studies have shown that separate genetic polymorphisms in
the genes encoding VEGF-A and its main receptor, VEGFR-2, pre-
dispose to either tumor response or the development of HTN in




ACE inhibitors Enalapril 5–40 mg/12–24 h
Lisinopril 5–20 mg/12–24 h
ARA II Valsartan 80–320 mg/24 h
Irbesartan 150–300 mg/24 h
Thiazides Hydrochlorothiazide 12.5–50 mg/24 h
Chlorthalidone 12.5–25 mg/24 h
Beta-blockers Bisoprolol 2.5–10 mg/24 h
Nebivolol 2.5–5 mg/24 h
Calcium antagonist Amlodipine 2.5–10 mg/24 h
ACE inhibitors: Angiotensin converting enzyme inhibitors; ARA II: angiotensin II
receptor antagonist.
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Importantly, the development of hypertension on VEGF-tar-
geted therapy correlates with improved cancer outcomes and,
therefore, could represent a biomarker useful for selecting the
subset of patients with the best chance of responding to anti-
angiogenic therapy.
Before the initiation of sunitinib, patients should be assessed for
preHTN. Those showing preHTN should receive antihypertensive
treatment for 3–7 days before starting sunitinib, and subsequent
regular monitoring of BP is necessary. The selection of anti-
hypertensive medication should be based on the general cardio-
vascular status of the patient, as well as taking into account inter-
actions and contraindications with other drugs. Strong CYP3A4 in-
hibitors such as ketoconazole may increase sunitinib plasma con-
centrations. Selection of an alternate concomitant medication with
no or minimal enzyme inhibition potential is recommended. A dose
reduction for sunitinib should be considered when it must be co-
administered with strong CYP3A4 inhibitors. AS CYP3A4 inducers
such as rifampin may decrease sunitinib plasma concentrations, a
dose increase for sunitinib should be considered when it must be
co-administered with CYP3A4 inducers [34].
No clear recommendations for speciﬁc antihypertensive
therapies can be made. Nevertheless, there is some evidence
supporting the selection of particular antihypertensive drugs
based on the patient’s status, as described in the European Society
of Cardiology guidelines [35].
Antihypertensive medications included beta-blockers, calcium
channel blockers, angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor blockers (ARBs), mineral-corticoid antagonists,
and diuretics; the loop diuretic furosemide is excluded as it is fre-
quently prescribed for management of edema (Table 1). Preference
for vasodilatory drugs, such as ACEI, angiotensin II receptor blockers,
or calcium channel antagonists is based on the vasoconstrictive ac-
tivity of the tyrosine kinase inhibitors [36]. Additionally, the potential
impact of CYP3A4 induction or inhibition with sunitinib should be
considered. In this sense, calcium channel blockers, such as ver-
apamil or diltiazem, should be avoided. Although high BP has been
proposed to reﬂect the clinical efﬁcacy of VEGF signal inhibition with
targeted treatment, control of HTN is essential to avoid serious ad-
verse events without detrimental antitumor activity.
In most patients, HTN can be controlled with standard anti-
hypertensive drugs. However, the biological effect of these anti-
hypertensive medications on angiogenesis and its implications should
be considered. Both enalapril and candesartan can inhibit myocardial
angiogenesis induced by VEGF. However, nifedipine has been shown
to induce VEGF secretion. Diuretics also have been used successfully to
manage increases in BP arising from cancer treatment; however,
thiazide-type diuretics should be used cautiously, particularly in pa-
tients prone to dehydration or hypercalcemia [37].The vasodilatory effect of NO has led to explore its use as a
hypotensive agent in patients treated with tyrosine kinase in-
hibitors. Nitrovasodilators such as glyceryl trinitrate, isosorbide
mononitrate and sodium nitroprusside act by releasing NO into
the vascular smooth muscle. They donate NO through mechanisms
involving the thiol groups of intracellular proteins [38].
Sodium nitroprusside produces hypotension by increasing the
NO-mediated generation of cGMP, which in turn causes vasodila-
tion. In addition, phosphodiesterase type 5 inhibitor augments
nitroprusside-induced hypotension.
Kruzliak et al. reported the use of NO donors in 3 patients
treated with bevacizumab þ/- chemotherapy. All patients devel-
oped HTN resistant to combinations of three or more clasic anti-
hypertensive drugs. However the BP normalized after use of
molsidomide, isosorbide dinitrate and isosorbide mononitrate,
respectively [39]. The autors conclude that NO donors could be
successfully used not only for the treatment of developed angio-
genesis-inhibitor-induced HTN but also for preventive effects.
In a later study Kruzliak et al. proposes a treatment algorithm,
distinguishing 3 groups of patients [40]:
1. Normotensive patients(o120/o80 mmHg). Blood pressure
measurement every two weeks, subsequently spaced if HTN is
not developed. No pharmacological trtamiento is needed.
2. Prehypertensive patients (120–130/80–89 mmHg). Weekly in-
itial BP measurement. It is not necessary to start drug treatment
unless organ damage is detected; in this case start NO donors
3. Hypertensive (4140/490 mmHg). Weekly initial BP measure-
ment. Start with NO and if blood pressure is not controlled add
other drugs.
4. In conclusion,VEGF signaling pathway has been recognized as
an important player in the development of RCC. Angiogenesis
inhibitors are useful drugs in the treatment of this disease, but
are associate with several side effects, with HTN being the most
common one. VEGF inhibitors-induced decrease in nitric oxide
synthase and nitric oxide production, that can result in vaso-
constriction and increased blood pressure. So NO donors may be
drugs of choice in the treatment of HTN associated with TKI, and
is necessary to explore prospectively its use to conﬁrm these
promising initial results.References
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